Traders Buy Shares of Gilead Sciences (GILD) on Weakness

Investors bought shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Thursday. $91.35 million flowed into the stock on the tick-up and $60.09 million flowed out of the stock on the tick-down, for a money net flow of $31.26 million into the stock. Of all equities tracked, Gilead Sciences had the 31st highest net in-flow for the day. Gilead Sciences traded down ($0.60) for the day and closed at $71.88

Several equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday. Raymond James restated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, November 1st. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, November 1st. Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Finally, Barclays boosted their price target on shares of Gilead Sciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 26th. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $87.84.

The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.39 and a current ratio of 3.45. The stock has a market cap of $93.76 billion, a price-to-earnings ratio of 8.32, a price-to-earnings-growth ratio of -2.81 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. During the same quarter in the previous year, the business posted $2.27 earnings per share. Equities analysts expect that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the transaction, the director now owns 3,067,762 shares in the company, valued at $239,408,146.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 150,000 shares of company stock worth $11,087,500 in the last quarter. Company insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of GILD. Bank of New York Mellon Corp grew its holdings in shares of Gilead Sciences by 199,789.8% in the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after purchasing an additional 31,335,030 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Gilead Sciences by 285.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 3,998,024 shares of the biopharmaceutical company’s stock worth $308,688,000 after purchasing an additional 2,959,697 shares during the last quarter. Swedbank grew its holdings in shares of Gilead Sciences by 103.7% in the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after purchasing an additional 1,988,987 shares during the last quarter. Natixis grew its holdings in shares of Gilead Sciences by 4,550.6% in the second quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock worth $135,555,000 after purchasing an additional 1,872,389 shares during the last quarter. Finally, Prudential Financial Inc. grew its holdings in shares of Gilead Sciences by 54.2% in the third quarter. Prudential Financial Inc. now owns 3,986,013 shares of the biopharmaceutical company’s stock worth $307,760,000 after purchasing an additional 1,400,820 shares during the last quarter. Hedge funds and other institutional investors own 78.09% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/11/10/traders-buy-shares-of-gilead-sciences-gild-on-weakness.html.

Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: Short Selling – Explanation For Shorting Stocks

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply